Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 4:33 pm Purchase | 2025-02-12 | 13D | Sera Prognostics, Inc. SERA | Baker Bros. Advisors LP | 5,498,170 16.100% | 63,771 (+1.17%) | Filing History |
| 2025-02-14 4:16 pm Purchase | 2024-12-31 | 13G | Immatics N.V. IMTX | Baker Bros. Advisors LP | 7,275,830 6.000% | 1,436,977 (+24.61%) | Filing History |
| 2025-02-14 4:15 pm Purchase | 2024-12-31 | 13G | Celcuity Inc. CELC | Baker Bros. Advisors LP | 2,678,553 7.200% | 803,575 (+42.86%) | Filing History |
| 2025-02-14 4:14 pm Purchase | 2024-12-31 | 13G | Candel Therapeutics, Inc. CADL | Baker Bros. Advisors LP | 2,981,983 6.800% | 2,981,983 (New Position) | Filing History |
| 2025-02-14 4:12 pm Sale | 2024-12-31 | 13G | Biomea Fusion, Inc. BMEA | Baker Bros. Advisors LP | 1,451,990 4.000% | -656,959 (-31.15%) | Filing History |
| 2024-12-31 4:18 pm Purchase | 2024-12-29 | 13D | Kala Pharmaceuticals, Inc. KALA | Baker Bros. Advisors LP | 1,201,894 19.700% | 310,559 (+34.84%) | Filing History |
| 2024-12-17 6:46 pm Purchase | 2024-12-13 | 13D | Bicycle Therapeutics plc BCYC | Baker Bros. Advisors LP | 10,885,357 22.900% | 1,485,397 (+15.80%) | Filing History |
| 2024-12-10 9:30 pm Sale | 2024-12-09 | 13D | BeiGene, Ltd. ONC | Baker Bros. Advisors LP | 125,276,610 13.000% | -13,401,427 (-9.66%) | Filing History |
| 2024-11-14 4:27 pm Purchase | 2024-09-30 | 13G | Sagimet Biosciences Inc. SGMT | Baker Bros. Advisors LP | 1,538,489 4.990% | 81,971 (+5.63%) | Filing History |
| 2024-11-14 4:26 pm Purchase | 2024-09-30 | 13G | Celcuity Inc. CELC | Baker Bros. Advisors LP | 1,874,978 5.100% | 1,874,978 (New Position) | Filing History |
| 2024-11-14 4:24 pm Purchase | 2024-09-30 | 13G | Stoke Therapeutics, Inc. STOK | Baker Bros. Advisors LP | 4,368,443 8.300% | 4,368,443 (New Position) | Filing History |
| 2024-11-14 4:23 pm Sale | 2024-09-30 | 13G | Achilles Therapeutics plc ACHL | Baker Bros. Advisors LP | 0 0.000% | -3,311,567 (Position Closed) | Filing History |
| 2024-11-14 4:21 pm Purchase | 2024-09-30 | 13G | Nurix Therapeutics, Inc. NRIX | Baker Bros. Advisors LP | 6,751,565 9.700% | 1,799,113 (+36.33%) | Filing History |
| 2024-11-14 4:21 pm Sale | 2024-09-30 | 13G | Aerovate Therapeutics, Inc. AVTE | Baker Bros. Advisors LP | 628,939 2.200% | -1,051,578 (-62.57%) | Filing History |
| 2024-11-14 4:20 pm Purchase | 2024-09-30 | 13G | Replimune Group, Inc. REPL | Baker Bros. Advisors LP | 11,045,336 16.200% | 1,500,000 (+15.71%) | Filing History |
| 2024-11-14 4:17 pm Sale | 2024-09-30 | 13G | Athira Pharma, Inc. ATHA | Baker Bros. Advisors LP | 0 0.000% | -3,153,807 (Position Closed) | Filing History |
| 2024-11-14 4:14 pm Purchase | 2024-09-30 | 13G | Edgewise Therapeutics, Inc. EWTX | Baker Bros. Advisors LP | 5,840,059 6.200% | 5,840,059 (New Position) | Filing History |
| 2024-11-14 4:11 pm Purchase | 2024-09-30 | 13G | AbCellera Biologics Inc. ABCL | Baker Bros. Advisors LP | 27,525,640 9.300% | 4,615,887 (+20.15%) | Filing History |
| 2024-10-10 5:01 pm Purchase | 2024-10-08 | 13D | Talis Biomedical Corporation TLIS | Baker Bros. Advisors LP | 2,507,193 65.600% | 2,507,193 (New Position) | Filing History |
| 2024-10-08 5:29 pm Purchase | 2024-10-04 | 13D | Kiniksa Pharmaceuticals, Ltd. KNSA | Baker Bros. Advisors LP | 3,151,029 7.700% | 3,151,029 (New Position) | Filing History |